OVERVIEW GOMEZ Emmanuel SQUEDIN Thomas LETURGEZ Thibaut DELEPIERRE

OVERVIEW GOMEZ Emmanuel SQUEDIN Thomas LETURGEZ Thibaut DELEPIERRE Alban

Institut Mérieux

• Silliker, headquartered in Chicago; • Institut Mérieux has a 89% holding in the company; • Within the Nutrition / Health division of Institut Mérieux, Silliker’s mission is both to improve nutrition and enhance the quality and safety of food products.

• Transgene, based in Strasbourg; • Biopharmaceutical company dedicated to treating infectious diseases and cancer. • Institut Mérieux has a 55% holding in the company; • It develops therapeutic vaccines and innovative immunotherapy products based on exclusive technologies for stimulating patient immune systems by using vectors for the expression of tumoral or infectious antigens in target cells.

Bio. Mérieux : Presentation Ø A world leader in the field of in vitro diagnostics for over 45 years. • Designs, develops, manufactures and markets Reagents, Automated instruments. • For medical analysis and quality control of products of agro-food, cosmetics and pharmaceuticals. Ø Contribute to the improvement of public health worldwide

History • Marcel Mérieux creates the Institute Mérieux, which developed a large range of vaccin and biological products. 1897 • Creation of BD Mérieux equally owned by Institute Mérieux and Becton Dickinson. 1963 • Alain Mérieux takes majority control of the company: BD Mérieux become Bio. Mérieux. 1974 • Different acquisitions. 2004 Until Now • Listing of Bio. Mérieux on the stock exchange. • Different acquisitions.

Global presence Ø Bio. Mérieux = a part of the Institut Mérieux group Bio. Mérieux is present in 150 countries.

Global presence Ø It has 17 production sites Distributed in France, the Netherlands, the United Kingdom, Italy, the United States, Brazil, Japan and Australia ØA European logistics center located in France. Ø Based in Marcy-l'Etoile, France Ø Employs 6000 people worldwide, 880 people are dedicated in bio. Mérieux, research, divided in 13 research centers in the United States, Brazil and Europe (Lyon - France, Florence - Italy, Boxtel - Country Netherlands).

Bio. Mérieux : Some results in 2008 Ø 8 th Global Society in diagnostic biological - AC 1 111 million Euros Realizes over 81% of its international business Anonymous Society, capital = 12. 029. 370 € Sales growth : + 9, 8% Cash flow : +19%

Status • Anonymous society (AS) is a corporation so named because his name does not reveal the names of shareholders it may not even know the identity when the company is on the stock exchange. • Conventional Structure : – A GD; – A Board of Directors (11); – General meetings.

Corporate Governance • Board of Directors, Chairman : Alain Mérieux. • Management Committee : 11 Alain Mérieux Alexandre Mérieux

CAPITAL

Stock-Market • Stock exchange data : – Number of shares : 39 453 740; – Capitalization of stock-market : 3 223. 77 MEUR; – Activity sector : Medical equipment; Share characteristics: Market: NYSE Euronext Paris; Stock symbol: BIM; Average daily trading volume in 2008: approximately 34, 700 shares => for a value of 2. 3 million euros.

SHARE PRICE PERFORMANCE IN 2009

Acquisitions 1986 1988 2001 • Acquisition of API reference global identification and manuals Antiobiogramme • Acquisition of VITEK, American company • Acquisition of Organon Teknika, diagnostic division of Akzo Nobel

2006 : Sales by technology

Economic model Very different business model from the pharmaceutical industry. 1. Highly diversified product portfolio less risk • In sales : no blockbuster • In the development pipeline 2. Shorter development cycles 3. No risk from generics 4. Lower product liability risk : In vitro vs In vivo

A promising market

The sentence

Strategy • From a strategy focused on the laboratory Infectious diseases, oncology and cardiology Industrial applications • To a strategy focused on pathologies and clinicians’ needs Infectious agents : clinical and industrial applications Tests delivering high medical value : Oncology Cardiology Point-of-care tests Theragnostics : therapeutics and diagnostics

Strategy Domain Technologies Growth Pathologies Industrial applications Infectious diseases Cancers Cardio-vascular diseases Diabet Clinical chemistry Endocrin Tests Blood analysis Auto-immun diseases TDM/DOA tests ** Bacteriology Molecular Biology Immunoassay Clinical Chemistry Hematology Hemostasis 2300 1800 8700 9100 1200 3% - 4% 10% - 12% 3% - 4% 4% -5% 3% - 4% Low Medium High Medium

Clinical applications become a major reference for doctors and biologists on key pathologies Partnerships with pharmaceutical / biotech companies specialized in these pathologies. Cross-functional approach by pathologies - One lead manager for each pathology Bacteriology Molecular biology Immunoassays Sepsis Bact/Alert Gene. Xpert VIDAS PCT Nosocomial infectious PPM, VITEK 2 Diversilab VIDAS CDA 2 Tuberculosis Bact/Alert Gen-Probe Infectious diseases VIH/Hepatitis easy. MAG/Easy. Q VIDAS HIV Cancers VIDAS PSA Cardio-vascular diseases VIDAS D-dimers

Commercializing network

Commercializing on the quality of commercial network 2007 – 2012 Growth rate* • Internal R&D pipeline • Sales network optimization 5 -6% 1%

Optimization of commercial network • Geographical priorities : United states and Japan • Sustained creation of new subsidiaries : Ø Algeria – 2007, South Africa – 2007, Ø Singapore – 2008, Dubai - 2008

Etablishment of a global department • Creating a world business management

Commercializing on the quality of commercial network • Pipeline after internal R&D • Optimization of commercial network • Business Development – Distribution agreement – Acquisitions : 5 -6% 1% 1 -2% • « Product companies » • … Total 7% - 9%* * : Compound annual growth rate

Industry Control

Industry Control leader sector consolidation Aim : 2012 a market share of 30%

Industry - Strategy Became the leader in industry consolidation Aim Internal growth External growth Assets • 2012 : a market share of approx. 30 % • PPM • Develop an automated multi-target genetic testing ( ADNA project ) • Agreements • Acquisitions • Undisputed Leadership • Capitalizing on the clinical commercial network

Partnerships • Copan – 2007 – Exclusive worldwide distribution agreement authorizing bio. Mérieux to market, for the pharmaceutical industry, an innovative sample collection system based on technology developed by Copan. – This patented product marks a major breakthrough because it is the first swab on market that can be used to perform a quantitative environmental control. The unique texture of the Nylon™ flocked swab picks up more microorganism than conventional swabs. It is specifically designed for aseptic manufacturing facilities control.

Acquisition for Industry Acquisitions 2007 2008 BTF, Australia To develop and market nextgeneration handheld diagnostic solutions for « Point-of-Care » PML microbiological, USA

BTF • Provides the world's most precise quantitative reference standards for microbiological testing. • Use to verify the performance of control methods. • Target customers in the industrial microbiology market, specifically testing water, food and pharmaceutical products • BTF’s range of products and expertise are a key addition to portfolio of solutions for microbiological control

Infectious diseases expertise

Infectious diseases Clinical diagnostic and industrial microbiology. • Independence and expertise field • International scope • 45 years of experience and know-how • Scientific and technological innovation – 13% of the sales in R&D – 3 main technologies • Bacteriology • Immunoassays • Molecular biology

Strategic plan 2007/2012 • Bacteriology: “be an incontrovertible leader” – Accelerate the complete automation of analysis processes – Focus on chromogenic media • Molecular biology: “become the key leader in sepsis and HAI” – Be the leader of molecular diagnostic automation of HIV and hepatitis – Biochips: launch of a multi-target genetic test PLC (ADNA project) • Immunoassays: “increase the number of high-medical-value tests and reinforce the Point of Care activity” – VIDAS/VIDIA : extend the product range – Patient’s Point of Care • Based on the expertise in infectious diseases, technical mastery and on a large number of products already on the market. • Positioning : Full automation & Point of care in clinical market

Areas of Expertise • • • Healthcare Associated Infections HIV Sepsis Tuberculosis CNS infections Gastro-intestinal infections Hepatitis Mother-to-child transmission Urinary tract infections Respiratory infections Sexually transmitted infections

Products and strategy • Improve the clinical presence (“Superbugs”, Theranostic …) • Transverse approach regarding pathologies: - One manager for each pathology - One sponsor for each pathology in the executive committee Partnerships with pharmaceuticals industries/biotechs working on those diseases.

Healthcare Associated Infections • • Among the 10 leading causes of mortality in industrialized countries. Impact on the length of hospitalization and related healthcare expenses. 5 billion$ annually in U. S. (WHO figures, 2005) Affect around 10% of hospitalized patients, 1. 4 million worldwide each day Often characterized by resistance to antibiotics • bio. Mérieux research: • • – New strains of drug-resistant bacteria: adding to collection of over 30, 000 bacterial stains, Centers for Disease Control (CDC) – Automation: Full Microbiology Lab Automation, futher reducing time to result for bacterial identification. – Chromogenic media: direct, reliable and rapid isolation of bacteria • • Prevention and surveillance: screening of patients, hospital environmental controls, epidemiological surveillance. Intervention: identification, antibiotic susceptibility testing, genotype characterization, identify the source of infection and prevent epidemics.

Sepsis • • • Sepsis is the leading cause of death in non-coronary intensive care units. Mortality from severe sepsis: 32 to 54% In developed countries: estimation of 3, 000 people die of severe sepsis a day. In US, total cost of 16. 7 billion dollars a year Due to the aging of the population, invasive diagnostic techniques and increasing bacterial resistance to antibiotics, the number of patients with sepsis is rising steadily worldwide. bio. Mérieux research: a race against the clock – Tests easier to use, at the patient point’s of care – Reduced time for the analysis of blood samples from several days to just 2 hours • Diagnostic: – Procalcitonin (PTC), introduced in VIDAS system. • 20 min to have early indications so the patient can be given adequate treatment • Same technology for monitoring antibiotic therapy and patient’s response to treatment – Bacterial identification and antibiotic susceptibility testing: VITEK 2 system, Etest® (MIC) – Automated blood culture: Bac. T/ALERT 3 D, rapid growth and detection.

FMLA – Full Microbiology Lab Automation TM To face challenges, automation = ü Standardization ü Speed ü Controlling healthcare costs ü Added value - Inoculation of Petridishes: PREVI Isola™ - Automated staining of sample slides: PREVI™ Color Gram - Urinary screening (detection of bacteria and particles): UF-1000 i - Blood culture: Bac. T/ALERT® - Identification of bacteria and automated antibiogram: VITEK® 2 - Genotyping of microbialstrains: Diversi. Lab™ - VIDAS® - Nucli. SENSEasy. Q® - Nucli. SENS® easy. MAG® A strategic partnership with Hitachi High-Technologies Corporation focused on microbiology and molecular 5 diagnostics

Patient’s Point of Care • Test performed and interpreted near the patient, by a physician or a nurse. • An estimatedmarket of $4 b – U. S. 65% of the market – Averagegrowth rate 10% a year • bio. Mérieux POC strategy – Manualrapid tests • Quick. Vue® tests: distribution agreement with. Quidel (2008) • Meikang Biotechrapid tests following acquisition (2010) – Handheld diagnostic solution – Partnership with Philips (2013)

Results - Q 4 2009 • Clinical field: 7, 4% sales increase – Extraction reagents (Nucli. SENS® easy. MAG®) – H 1 N 1 influenza – Interest in FMLA (audit asked) especially PREVI Isola and PREVI Color Gram – Immunoassays: VIDAS®, microplate screening, rapid testing

2009 Product Launches • bio. Mérieux expanded its line of automated screening tests for Methicillin Resistant Staphylococcus aureus (MRSA), one of the leading causes of healthcare-associated infections – In the US, chrom. ID™ MRSA, chromogenic media that enables visual identification of MRSA colonies in patient sample – In Europe, Nucli. SENSEasy. Q® MRSA, molecular diagnostic MRSA test on the Easy. Q® automated platform – For both emergency and routine patient situations • 17 new productswerebrought to marketduring the year: – – Nucli. SENSEasy. Q® HIV-1 v 2. 0, help FU of HIV positive patients VIDAS® EBV, detection of EBV, 80% of infectious mononucleosis cases VILINKTM, a secure network connection for VITEK® 2 installations VITEK® 2 PC 4. 02, software application compatible with European antimicrobial susceptibility standards (EUCAST)

Bacteriology - strategy

Bacteriology - Strategy Become the undisputed leader Aim • Accelerate the full automatisation of laboratory and analysis process • 2012 : market share of approx. 40% Internal growth • PPM • Blood culture : faster results thanks to new technologies • Identification and antibiogram : menu extensions External growth • Agreements • Acquisitions Assets • More than 40 years of experience • More than 50 % of the market in automated bacteriology

Partnerships • Cepheid - 2007 • The product menu comprises both bacterial and fungal identification assays as well a series of genetic markers for antibiotic resistance. – Cepheid is in charge of manufacturing – bio. Mérieux distributes the sepsis assays • Lab. Tech Systems - 2007 – signed an exclusive worldwide license agreement for Lab. Tech Systems’ automated pre-poured media (PPM) Micro. Streak®. • Eiken Chemical Co. , Ltd. (Japan) - 2007 – Production of PPM for Biomérieux by Eiken Chemical Co. • Sysmex (Japan) - 2008 – UF-1000 i is highly standardized and automated solution for urinary screening methods. • Quidel (USA) – 2008 – Exclusive distributor of Rapid diagnosis test for Quidel. (Except USA, Japan and Scandinavia)

Acquisitions for bacteriology Acquisitions 2007 Biomedics, Spanish A leader in Spain in the field of bacteriology ↗ production capabilities for culture media 2008 AB Biodisk, Swedish expert in antibiotic susceptibility testing in fastidious and unusual organisms. Commercialised epsilometer test Etest® PML microbiological, USA In vitro diagnostics company

Acquisition of PML microbiological v In vitro diagnostics company that provides culture media and microbiological products for both clinical and industrial applications. With this acquisition, bio. Mérieux is now : USA • one of the leading companies in the field of microbiological control for the pharmaceutical industry Canada • number one for the clinical culture media in Canada.

Molecular biology

Molecular biology - Strategy Become the leader in sepsis and hospital-acquired infections Aim • Achieve a market share of 8% Internal growth • Extend the Nucli. Sens Easy. Q platform menu • Develop an automated multi-target genetic testing ( ADNA project ) External growth • Agreements • Acquisitions Assets • Expertise across the chain : extraction, amplification, detection • Ability to capitalize on know-how in infections

Partnerships • Nu. GEN Technologies Announce Cross-License and Supply Agreement. (USA) - 2007 – Nu. GEN's exclusive WT-Ovation RNA Amplification System. – enhances Biomérieux amplification capabilities for clinical use. • Advan. Dx (USA) - 2007 – To provide rapid results for Bloodstream results. – identification of bacteria and yeast from positive blood cultures in less than three hours. • Hitachi High-Technologies (Japan) – 2008 – R&D partnerships Focus on Microbiology and Molecular Diagnostics

Immunoassays

Immunoassays - Strategy Extend the high medical-value test menu and strengthen the point of care business Aim • VIDAS / VIDIA : strengthen the franchise • Point of care : develop an manual and semiautomated range Internal growth • VIDAS : optimize the installed base with new high medical-value test • VIDIA : develop tests for routine • Point of care : introduction a rapid test reader Assets • Installed base of more than 20, 000 instruments • Expertise in antibodies

Partnerships and Acquisitions 2010 Partnerships Acquisition Philips To develop and market nextgeneration handheld diagnostic solutions for « Point-of-Care » Chinese Rapid Test Manufacturer Meikang Biotech Reinforce bio. Mérieux’s position in the Point-of. Care and rapid test markets for both emerging and deveped countries

China Strategy

bio. Mérieux in China today • A long-standing presence – Since 1978 – 1992: Hong Kong – 2005: HQ moved to Shanghai • 5 offices and more than 100 FTE • A large distributor network • A strategic foot hold in China – – A large site and a strong team (mid-2010) China becomes bio. Mérieux 3 rd corporate pillar Research team in Fudan University Cancer Hospital (Shanghai) Joint-venture with Shanghai Kehua Bio-engineering (microplates) • POC strategy : Manual rapid tests&Philips partnership • Meikang Biotech acquisition; « this adds up »

Meikang. Biotech Activites synergy • A well-establishedc ompany, Dr Chang - 1992 – 150 employees, 100 contractors – Sales about € 5 M – A wideproduct range: rapid tests • • Infectious diseases Carido-vascular and oncology Drugs of abuse Pregnancy and hormone testing • A fully-owned manufacturing site in Shanghai – 9, 000 m 2 on 2 hectares of land – 30 million tests per year – Certifications: GMP, ISO 9001, ISO 13485, Manufacturing license class III (Shanghai FDA)

Meikang. Biotech Higher ambitions for the Group • Support business growth in China – Rapid tests ideally complementing bio. Mérieux’s product offering, mainly for infectious diseases – In the coming years: additional production capacities • Optimize cost structure of products for developing countries • Leverage R&D expertise and develop innovative products – Additional immunoassay R&D capabilities for new rapid tests – A beachhead for the rapid diagnostics and POC markets

Theranostics

Theranostic The good drug for the good patient at the good time A theranostic is a diagnostic test that helps clinicians make the right therapeutic decision for the right patients, enabling a more personalized approach to medicine.

Theranostic Microbiology Oncology

« Le theragnostic devrait déboucher sur un fort développement commercial après 2012 »

The Scientific need • The overall five-year survival rate is still only 66%. Causes for this high mortality rate include : – late diagnosis – challenging tumor identification and classification – inappropriate treatment, all of which lead to poorer patient outcomes

Partnerships - Cancer • Leading Biotech for discovery and validation of molecular discovery validation biomarkers and proteomics, • particularly for early detection and prediction of treatment efficacy : – Exon. Hit (France): breast, colon and prostate – Proteo. Sys (Germany): prostate cancer • Other partners contribute their expertise: – French Atomic Energy Commission (CEA) – the French National Scientific Research Center (CNRS) – the Lyon University Hospitals (HCL) – ST Microelectronics (ST) – Claude Bernard University in Lyon (UCBL).

Biomarkers Development

Plan 2007 -> 2012

Theranostics: flexible way to work Gsk Merck and Ipsen Co-development of a Co-development predictive test with payers. diagnostic tests and the Determine which of new drugs treatment is best suited to Opportunity for label different populations of integration and patients suffering from co-marketing breast cancer

Sept. 17, 2007. Patership in theragnostic development • Co-funded The development of a companion test for BN 83495; intended for both : – Clinical development of the compound – Diagnostic test potentially for future commercialization • The test will be developed on Nucli. SENS Easy. Q® molecular diagnostics platform. NASBA® amplification technology. (CLIA certified laboratory) • Tumour marker tests – determining the molecular signature of tumours – guiding a rational choice of treatment for defined patient groups.

The Target • Novel breast cancer therapy • designed to block the steroid sulfatase enzyme (STS). sulfated steroid precursors estrogens STS during pregnancy • Found in hormone-dependent breast cancer in postmenopausal women, but not BMI. Role of steroid sulfatase in local formation of estrogen in post-menopausal breast cancer patients. Nakata T, Takashima S, Shiotsu Y, Murakata C, Ishida H, Akinaga S, Li PK, Sasano H, Suzuki T, Saeki T. Pharmaceuticals Research and Development Division Kyowa Hakko Kogyo, Tokyo, Japan. taisuke. nakata@kyowa. co. jp

BN 83495 : Phase I A first clinical study of Phase I the results demonstrate the inhibition of sulfatase enzyme doses tested in tumor biopsies A second phase I Optimization dose of BN 83495 in postmenopausal patients who have an advanced breast cancer hormone receptor positive.

Theranostics flexible way to work Gsk Merck and Ipsen Co-development of a Co-development predictive test. diagnostic tests and the Determine which of new drugs treatment is best suited Opportunity for label to different populations integration and of patients suffering co-marketing from breast cancer

Tyverb, lapatinib • Lapatinib is an oral small-molecule • inhibitor of the Erb. B 2/ Erb. B 1 TK receptor. Trastuzumab Lapatinib

Tyverb, lapatinib • Develop in breast cancer • Over expression of these receptors has been reported in a variety of human tumors. (squamous cell/gastric cancer) • Associated with poor prognosis and reduced overall survival. (agresive form of advanced breast cancer) • • • Limits Not in Monotherapy Poso: 5 tablets/ day, every days 2174€ / month 2 x 70 tablets = 2537, 74 € Adverse reactions, at least 10% of patients (Gastrointestinal, dermatologic, fatigue…)

Approval and funded Lapatinib received approval in june 2008 FDA - EMEA • 1 st indication: In combination with Xeloda (growth inhibitor) for a particular type of aggresive breast cancer : Erb. B 2+. After treatment with standard chemotherapy regimes including intravenous trastuzumab • 2 nd indication in combination with letrozole (aromatase inhibitor) for the first-line treatment of HER 2 -positive metastatic breast cancer in postmenopausal women. FDA • 3 thr indication in combination with letrozole (aromatase inhibitor) for the first-line treatment of HER 2 -positive metastatic breast cancer. • Refusal to pay for lapatinib as a 1 st-line and 2 nd-line treatment for HER 2 positive breast cancer (EGF 30008) =>finding it was not cost-effective.

Cost-effectiveness • Analysis lapatinib + capecitabine vs capecitabine monotherapy • the QALY gain was 0. 171 at an incremental cost of £ 13, 873 • Incremental cost-effectiveness ratio (ICER) of £ 81, 251 per QALY gained. Max £ 35, 000 • the cost effectiveness of lapatinib was particularly influenced by the extent of trastuzumab use post progression and the progression free patients receiving trastuzumab.

COMMISSION DE LA TRANSPARENCE Avis 16 juillet 2008 • L’EMEA a attribué à TYVERB une AMM conditionnelle, en l’absence : - de données robustes sur l’efficacité de TYVERB sur l’incidence des métastases cérébrales - et de démonstration sur la survie globale. • Le rapport bénéfice/risque sera réévalué annuellement. La firme s’est engagée auprès de l’EMEA : - données de survie : étude EGF 100 151 - phase III comparative vs HERCEPTIN Evaluer l’effet de TYVERB sur l’incidence des métastases cérébrales =site de rechute (Le rapport final soumis en mai 2013).

November 17, 2009 • Development of a predictive test => treatment best suited to different populations suffering from breast cancer. • ”This test will be developed from new biomarkers. After approval by regulatory agencies, it can be used for both cancer receiving adjuvant therapy and metastatic cancer” • Test Erb. B 2 / Erb. B 1 ? ? ? • GSK did not reveal the specific breast cancer drugs that the predictive test would accompany.

Oncology pipeline

• GSK's decision to work with Bio. Merieux: capacity to scale up the development and marketing of the test. (not only a biotech) • GSK : Opportunity for label integration and co -marketing

Aviara. Dx acquisition En septembre 2008 le Groupe a acquis la société Aviara. Dx, Inc. spécialisée en diagnostic moléculaire des tissus tumoraux à partir de biopsies. Accrédité par un CAP

THEROS Breast Cancer Index. SM Breast cancer recurrence • Breast cancer patients are typically classified by 3 factors low • 40% to 50% percent of breast cancer patients are inaccurately classified as “intermediate risk” according to St. Gallen’s risk assessment guidelines. intermediate – under-treated=> overall survival high-risk – over-treated=> cost, side effect • Better classification means better treatment selection • Test is a combination of 2 independent tests: – ER and PR , endocrine therapy. – Tumors , be sensitive or resistant to chemotherapy.

THEROS technology • THEROS Breast Cancer ℠ and THEROS Cancer. TYPE ID® – – – – objective diagnostic tool quantifiable Practical clinically impactful. faster, effective avoid expensive • real time RT-PCR based assays compatible with many form of samples. – extraction of RNA – reverse transcription to c. DNA – quantitative measurement using real time PCR

THEROS Cancer. TYPE ID® 1. 4 million new cases ofcancer in the US, 3 to 5% of new cancer are « cancer of unknown primary » ; Diagnotisis: -lengthy -expensive: $18, 000* • Diagnostic tools used studying cells and tumors with microscopes, laboratory cell stains , imaging • often fall short of identifying where a cancer started and what type it is. • Molecular diagnostics provides important information for cancer type identification • The price of a Cancer type test is 3600$ • Recognize over 75% of solid tumors. activity levels of 92 genes distinguish up to 39 different tumor types and 64 subtypes *Schapira DV, Jarrett AR. The need to consider survival, outcome, and expense when evaluating and treating patients with unknown primary carcinoma. Arch Inter Med. ; 155: 2050 -2054, 1995.

• SAN DIEGO Breast Cancer Symposium December 12, 2009 three studies using the company’s breast cancer molecular test (leader d’opinions)

http: //www. biotheranostics. com/wp-content/uploads/Test-Requisition-Form-website. pdf a two-year agreement with Lab 21 to commercialize the bio. Theranostics THEROS Cancer. TYPE ID

Conclusion

Clear objectives • a strategy focused on patients and pathologies – Infectious agents : clinical and industrial applications – high medical-value tests : oncology, cardiology, point of care and theragnostics • Strategy that leverages their strenghs – Bacteriology : leadership – Industry : lead sector consolidation – Molecular biology : become the leader on sepsis and hospital-acquired infections – Immunoassays : extend the high medical-value test menu and strengthen the point of care business – Theranostics : become a preferred partner for pharmaceutical and biotech compagnies

Good financial results for the third quarter Sysmex : Biomerieux become Sysmex’s global partner for distributing UF 1000 i Acquisition of BTF Institut Mérieux sells Laboratoire Marcel Mérieux shares its CEO Cepheid : Relationship in the development and commercialization of an innovative line of sepsis test products Aviara. Dx acquisition + Bad financial results in USA 1 Flu threat

SWOT

Future Acquisitions ? • Biomonitor ? – Danish biotechnology company leader in thenostics and combine development of innovative and proprietary clinical bioassays. – Products : i. Lite™ Products based upon the « gene reporter » technology. • Exonhit ? – A world leader in the exploitation of alternative RNA splicing. – Is ability to identify genes whose splice variants produce abnormal proteins can be used to develop tests for diagnosing diseases at an early stage.

Conclusion

Who wants to work at bio. Mérieux Name Opinion Alban +++ Emmanuel +++ Thibaut +++ Thomas +++